CN111356472A - 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 - Google Patents

使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 Download PDF

Info

Publication number
CN111356472A
CN111356472A CN201880075369.5A CN201880075369A CN111356472A CN 111356472 A CN111356472 A CN 111356472A CN 201880075369 A CN201880075369 A CN 201880075369A CN 111356472 A CN111356472 A CN 111356472A
Authority
CN
China
Prior art keywords
dose
subject
once
dulaglutide
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880075369.5A
Other languages
English (en)
Chinese (zh)
Inventor
D.A.科克斯
Z.米利塞维奇
谭丽珊
A.G.维尔纳
D.B.伍德沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64572530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111356472(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202510640885.XA priority Critical patent/CN120478602A/zh
Publication of CN111356472A publication Critical patent/CN111356472A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201880075369.5A 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物 Pending CN111356472A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510640885.XA CN120478602A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589244P 2017-11-21 2017-11-21
US62/589244 2017-11-21
PCT/US2018/060716 WO2019103875A2 (en) 2017-11-21 2018-11-13 Methods of using and compositions containing dulaglutide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510640885.XA Division CN120478602A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Publications (1)

Publication Number Publication Date
CN111356472A true CN111356472A (zh) 2020-06-30

Family

ID=64572530

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510640885.XA Pending CN120478602A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物
CN201880075369.5A Pending CN111356472A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202510640885.XA Pending CN120478602A (zh) 2017-11-21 2018-11-13 使用杜拉鲁肽的方法和含有杜拉鲁肽的组合物

Country Status (21)

Country Link
US (2) US11576950B2 (enExample)
EP (1) EP3713593A2 (enExample)
JP (3) JP7221956B2 (enExample)
KR (2) KR20220146656A (enExample)
CN (2) CN120478602A (enExample)
AU (2) AU2018372709B2 (enExample)
BR (1) BR112020007817A2 (enExample)
CL (1) CL2020001252A1 (enExample)
CR (1) CR20200202A (enExample)
DO (1) DOP2020000104A (enExample)
EA (1) EA202090971A1 (enExample)
EC (1) ECSP20026436A (enExample)
IL (1) IL274563B2 (enExample)
JO (1) JOP20200126A1 (enExample)
MA (1) MA50798A (enExample)
MX (1) MX2020005231A (enExample)
PE (1) PE20200847A1 (enExample)
PH (1) PH12020550795A1 (enExample)
SG (1) SG11202003687RA (enExample)
UA (1) UA127588C2 (enExample)
WO (1) WO2019103875A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020190591A1 (en) * 2019-03-15 2020-09-24 Eli Lilly And Company Preserved formulations
AU2021213682B2 (en) * 2020-01-30 2025-05-29 Eli Lilly And Company Therapeutic uses of dulaglutide
EP4153130A1 (en) * 2020-05-19 2023-03-29 F. Hoffmann-La Roche AG The use of chelators for the prevention of visible particle formation in parenteral protein solutions
CA3223313A1 (en) 2021-06-23 2022-12-29 Eli Lilly And Company Methods of using and compositions including an incretin analog

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730523A (zh) * 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
CN106559984A (zh) * 2014-05-29 2017-04-05 韩美药品株式会社 用于治疗糖尿病的包含长效胰岛素类似物缀合物和长效促胰岛素肽缀合物的组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
NZ543292A (en) 2003-06-12 2008-04-30 Lilly Co Eli GLP-1 analog fusion proteins
CN101044162B (zh) 2004-12-22 2010-10-27 伊莱利利公司 Glp-1类似物融合蛋白质制剂
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
CN110650747A (zh) 2017-06-01 2020-01-03 伊莱利利公司 用于治疗慢性肾病的杜拉鲁肽

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730523A (zh) * 2007-07-10 2010-06-09 伊莱利利公司 GLP-1-Fc融合蛋白质制剂
CN106559984A (zh) * 2014-05-29 2017-04-05 韩美药品株式会社 用于治疗糖尿病的包含长效胰岛素类似物缀合物和长效促胰岛素肽缀合物的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SMITH ETAL: "Dulaglutide(Trulicity)The Third Once-Weekly GLP-1 Agonist", 《PHARMACY AND THERAPEUTICS》 *
熊丽等: "《生物化学实验教程》", 31 August 2011, 华中师范大学出版社 *

Also Published As

Publication number Publication date
US11576950B2 (en) 2023-02-14
JP2021502379A (ja) 2021-01-28
JOP20200126A1 (ar) 2020-05-21
IL274563A (en) 2020-06-30
US20240189394A1 (en) 2024-06-13
SG11202003687RA (en) 2020-06-29
JP7221956B2 (ja) 2023-02-14
EP3713593A2 (en) 2020-09-30
AU2022203372A1 (en) 2022-06-09
MX2020005231A (es) 2020-08-24
AU2018372709A1 (en) 2020-05-14
ECSP20026436A (es) 2020-06-30
KR20220146656A (ko) 2022-11-01
EA202090971A1 (ru) 2020-08-07
WO2019103875A2 (en) 2019-05-31
CN120478602A (zh) 2025-08-15
PH12020550795A1 (en) 2021-04-19
DOP2020000104A (es) 2020-08-31
IL274563B1 (en) 2023-08-01
NZ763815A (en) 2023-11-24
BR112020007817A2 (pt) 2020-10-06
AU2022203372B2 (en) 2025-04-10
WO2019103875A3 (en) 2019-07-25
UA127588C2 (uk) 2023-10-25
JP2024056908A (ja) 2024-04-23
US20200330558A1 (en) 2020-10-22
KR102589234B1 (ko) 2023-10-16
CR20200202A (es) 2020-08-20
JP2022062153A (ja) 2022-04-19
PE20200847A1 (es) 2020-08-18
CL2020001252A1 (es) 2020-10-30
MA50798A (fr) 2020-09-30
CA3082625A1 (en) 2019-05-31
AU2018372709B2 (en) 2022-04-28
KR20200076705A (ko) 2020-06-29
IL274563B2 (en) 2023-12-01

Similar Documents

Publication Publication Date Title
JP7665674B2 (ja) 前立腺癌を治療するための組成物
AU2022203372B2 (en) Methods of using and compositions containing dulaglutide
JP2024129139A (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
KR20190044673A (ko) 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법
CN107496907A (zh) 诱导ii型糖尿病患者体重减轻或/和防止ii型糖尿病患者体重增加的药物组合产品
WO2023280152A1 (en) Combination therapy for treatment of liver diseases
JP2025509278A (ja) 小細胞肺癌を治療する方法
KR20230132627A (ko) 둘라글루티드의 치료적 용도
Madsbad et al. Treatment with GLP-1 receptor agonists
CA3082625C (en) Methods of using and compositions containing dulaglutide
AU2021293980B2 (en) Treatment of food allergy using anti-IgE antibodies
CN114096269B (zh) 高浓度胰岛素制剂
EA041605B1 (ru) Способы применения и композиции, содержащие дулаглутид
KR20180102091A (ko) 당뇨병의 치료를 위한 약제학적 제제
WO2022183418A1 (zh) 抗vegf抗体制剂
CN114980917A (zh) 杜拉鲁肽的治疗用途
WO2021052472A1 (zh) 抗pcsk9抗体用于预防或治疗胆固醇相关疾病的方法
McKeirnan et al. Immunizations and Diabetes
Samuel et al. A Retrospective Comparison Study between the Effectiveness and Safety of Fixed Dose Combination of Vildagliptin versus Sitagliptin with Metformin in Type 2 Diabetes Mellitus Patients
Schreiber et al. T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4)
Fasanmade et al. T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease
Hanauer et al. T1130 Efficacy of Delayed-Release Oral Mesalamine in Patients Who Received Previous Ulcerative Colitis Treatment
Hanauer et al. T1131 Steroid-Free Remission Over 2 Years in Crohn's Patients Receiving Adalimumab: the Open-Label Extension of the CHARM Trial
CN114761419A (zh) 用于治疗肥胖症的使用胰高血糖素和glp-1共激动剂的组合疗法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination